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Abstract
Background
Few studies have evaluated the coexistence of bronchiectasis (BE) and chronic obstructive
pulmonary disease (COPD) in series of patients diagnosed primarily with BE. The aim of
this study was to analyse the characteristics of patients with BE associated with COPD
included in the Spanish Bronchiectasis Historical Registry and compare them to the remain-
ing patients with non-cystic fibrosis BE.
Methods
We conducted a multicentre observational study of historical cohorts, analysing the charac-
teristics of 1,790 patients who had been included in the registry between 2002 and 2011.
Of these, 158 (8.8%) were registered as BE related to COPD and were compared to the
remaining patients with BE of other aetiologies.
Results
Patients with COPD were mostly male, older, had a poorer respiratory function and more fre-
quent exacerbations. There were no differences in the proportion of patients with chronic
PLOS ONE | https://doi.org/10.1371/journal.pone.0177931 May 18, 2017 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: De la Rosa D, Martı´nez-Garcia M-A, Giron
RM, Vendrell M, Olveira C, Borderias L, et al.
(2017) Clinical impact of chronic obstructive
pulmonary disease on non-cystic fibrosis
bronchiectasis. A study on 1,790 patients from the
Spanish Bronchiectasis Historical Registry. PLoS
ONE 12(5): e0177931. https://doi.org/10.1371/
journal.pone.0177931
Editor: Sanjay Haresh Chotirmall, Lee Kong Chian
School of Medicine, SINGAPORE
Received: December 18, 2016
Accepted: May 5, 2017
Published: May 18, 2017
Copyright: © 2017 De la Rosa et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
bronchial colonisation or in the isolated microorganisms. A significantly larger proportion of
patients with COPD received treatment with bronchodilators, inhaled steroids and intrave-
nous antibiotics, but there was no difference in the use of long term oral or inhaled antibiother-
apy. During a follow-up period of 3.36 years, the overall proportion of deaths was 13.8%.
When compared to the remaining aetiologies, patients with BE associated with COPD pre-
sented the highest mortality rate. The multivariate analysis showed that the diagnosis of
COPD in a patient with BE as a primary diagnosis increased the risk of death by 1.77.
Conclusion
Patients with BE related to COPD have the same microbiological characteristics as patients
with BE due to other aetiologies. They receive treatment with long term oral and inhaled anti-
biotics aimed at controlling chronic bronchial colonisation, even though the current COPD
treatment guidelines do not envisage this type of therapy. These patients’ mortality is nota-
bly higher than that of remaining patients with non-cystic fibrosis BE.
Introduction
Commercial development and scientific research related to bronchiectasis (BE) were scarce
throughout most of the 20th century due to the low prevalence of this disease as a consequence
of continuous health improvements, to such an extent that it became an “orphan disease” [1].
We are now going through a phase in which this disease is receiving great attention as a result
of better diagnosis via thoracic high-resolution computed tomography (HRCT), increased sci-
entific evidence on the effect of drugs such as macrolides or inhaled antibiotics and the estab-
lishment of new BE aetiologies [2]. There has been some controversy in recent years, however,
as regards whether chronic obstructive pulmonary disease (COPD) [3] should be recognised
as a BE aetiology, given the absence of any evidence proving a causal relationship, although
studies have increasingly shown a high prevalence of BE in COPD patients, particularly those
with more advanced stages of the latter disease [4,5]. The coexistence of both diseases causes
more symptoms, an accelerated functional decline, further complications and increased mor-
tality [6–9]. However, most data come from series of patients with COPD and there are few
studies that evaluate the coexistence of both diseases in series of patients diagnosed primarily
with BE.
The creation of BE registries is helping us obtain epidemiological and clinical data about
this disease, including its relationship with COPD. In population-based registries, information
is collected from all those centres where patients with an initial diagnosis of BE are diagnosed
and/or treated, which makes it possible to estimate the scale of the disease in the correspond-
ing geographical areas [10]. This overview facilitates the control of selection biases when con-
ducting epidemiological studies. The Spanish Bronchiectasis Historical Registry (SBHR) was
founded in 2002 by the Spanish Society for Pneumology and Thoracic Surgery (SEPAR). Its
aim was to collate a large number of BE patients to further the understanding of the disease
and identify its most common causes and clinical characteristics, as well as the most com-
monly isolated microorganisms and the most commonly followed treatment regimens.
The aim of this study is to analyse the characteristics of the patients diagnosed with BE
related to COPD who are included in the SBHR and compare them to the remaining patients
with non-cystic fibrosis (CF) BE.
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Material and methods
We conducted a multicentre observational study of historical cohorts by analysing adult
patients included in the SBHR between June 2002 and November 2011 who had been diag-
nosed with BE in various specialised outpatient clinics throughout Spain.
Structure of the registry
The SBHR was an electronic database, accessible through the SEPAR website (www.separ.es/
bronquiectasias), to which all affiliated pulmonologists were invited to contribute. The inclu-
sion criteria were a primary diagnosis of BE, obtained via thoracic CT, bronchography or,
exceptionally, clinical-radiological criteria. Data were entered into an electronic form divided
into five sections: identification/clinical data, aetiology, bronchial colonisation, lung function
and current treatment regimen. Each patient was examined by the SBHR coordination team
before being validated. In case of omissions or inconsistencies, applicable corrections were
requested from the corresponding researcher as a quality-control measure.
Study population
In this study, we analysed every patient included in the SBHR with non-CF BE. We rejected
those with CF, since this group shows very specific clinical and evolutive characteristics. The
cases in which COPD was considered a BE-associated disease were compared to the remaining
cases.
Registry variables
The SBHR collected several clinical data: age, gender, height/weight, year in which symptoms
started, year in which the BE was diagnosed, smoking history, presence and type of expecto-
ration (white, white-yellow or green), presence of haemoptysis and/or sinusitis, exacerbations
and mortality. An exacerbation was defined as an acute and sustained presentation of changes
in the characteristics of sputum (increased volume, consistency, purulence or haemoptysis),
and / or increased dyspnoea not due to other causes [11]. Information about the BE diagnosis
method was requested: CT, HRCT, bronchography or clinical-radiological criteria. The BE
extension was also recorded as localised, bilateral or diffuse (if it affected 4 lobes or more).
Researchers were asked to include the data of the spirometry performed closest to the
moment of inclusion in the registry, with the patient in a stable condition. As recommended
in the SEPAR guidelines for performing spirometry, post-bronchodilator values were used in
cases where this test was performed. The lung function data requested were: absolute values of
forced vital capacity (FVC) and maximum expiratory volume in one second (FEV1) in l/s,
FEV1/FVC ratio and oxygen saturation (SatO2). Subsequently, the theoretical values of FVC
and FEV1 were calculated through the formulas of Roca et al [12].
Researchers had to assign an aetiology to the BE of each patient. To ensure that the data
were as homogeneous as possible, researchers were urged to follow specific recommendations
proposed by SEPAR concerning the aetiological diagnosis. These recommendations were later
included in the SEPAR 2008 Bronchiectasis Diagnosis and Treatment Guidelines [11]. In cases
where BE was considered to have an unknown aetiology, a record of the diagnostic tests used
to rule out specific BE causes was requested [11]. It was left to each researcher’s discretion to
assign COPD or asthma as the cause of BE in a given patient, but a recommendation was made
to reasonably exclude any other possible aetiology. The COPD diagnosis was based on the
GOLD Guidelines in force since 2002 [13]. If a diagnosis of COPD-related BE was established
in a patient without obstructive pattern in the spirometry incorporated in the registry, the
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coordinating team contacted the physician responsible for the diagnosis to confirm that spi-
rometries had ratified the obstruction at some point of his clinical evolution and thereby sup-
ported the diagnosis. Otherwise, the patient was not considered to have COPD and was
transferred to the idiopathic BE group. Thus, COPD-related BE was established only if the
diagnosing physician thought, in addition to the confirmation of spirometric obstruction, that
COPD was a key factor due to smoking and medical history, or due to the presence of emphy-
sema in CT (data not recorded in the registry). Moreover, COPD was excluded as a BE-associ-
ated disease in many smokers with an obstructive spirometric pattern, if COPD was not
considered by the researcher to be responsible for the BE or clinical symptoms, and if these
patients presented some other condition that clearly influenced their clinical evolution and
could therefore be considered the main cause of BE.
All patients with three or more positive cultures for the same microorganism during a
period of 6 months, in different samples taken at intervals of one month, were considered to
have chronic bronchial colonisation (CBC) [14]. The researcher had to classify each patient as
either colonised or not colonised at the point of inclusion in the registry.
Furthermore, the current treatment regimen at the time of patient inclusion in the registry
was requested: oral antibiotic therapy (in exacerbations, cyclic or continuous), inhaled antibi-
otic therapy (cyclic or continuous), intravenous antibiotic therapy, bronchodilator treatment
(BD), inhaled corticosteroids (ICS) or surgical treatment.
Ethics statement
Researchers guaranteed patients’ confidentiality, in accordance with the data protection law
[15] by making their identification data anonymous and by using alphanumeric codes. Infor-
mation analysis was always aggregated, never individual. Every researcher agreed to comply
with the Guidelines to Good Clinical Practice.
Statistical analysis
We conducted a descriptive analysis with central tendency and dispersion measures for quan-
titative variables (mean and standard deviation) and frequency distribution for qualitative var-
iables. The T-Student test (or the ANOVA test in those cases with three or more categories)
was used to compare independent quantitative variables; the Chi-square test was used for inde-
pendent categorical variables.
In order to assess whether the presence of COPD in patients with BE was associated with
increased mortality, a survival analysis was conducted using the Cox regression with the follow
up data available in the SBHR. This analysis was adjusted for those variables which, according
to researchers, were clinically relevant, such as age, gender, body mass index, CBC by PA,
FEV1 (% predicted), smoking habit (active, previous smoker or always non-smoker) and BE
extension (localised, bilateral or diffuse). The survival analysis was graphically represented by
the Kaplan Meier curves and the log-rank test was used to compare the curves.
Results
Between June 2002 and November 2011, 2,113 patients from 36 health centres in 11 different
autonomous communities were included prospectively in the SBHR. 287 of these (13.6%) had
CF BE and were excluded from the current study. We have also excluded 36 more patients due
to incomplete or incorrect data (Fig 1). We have, therefore, analysed the remaining 1,790
patients with non-CF BE. 158 of these (8.8%) were registered as having BE related to COPD.
The remaining registered aetiologies were: unknown (27.7%), post-tuberculous (21.2%), non-
tuberculous infection (13%), primary immunodeficiencies (10.7%), asthma (6.1%), ciliary
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disease (3.3%) and up to 21 further aetiologies. A complete list of individual and grouped
aetiologies can be seen in S1 File.
General, radiological and clinical data
There were differences in the BE diagnostic method between non-COPD patients and COPD
patients (p = 0.026). The methods used were HRCT (84.8% vs. 77.2% of the cases, respectively),
conventional CT (14.4% vs. 22.2%) and bronchography (0.8% vs. 0.6%). As shown in Table 1,
there was a significantly higher percentage of men in the COPD group: they were older at the
time of inclusion in the registry, at the onset of symptoms and at the time BE was diagnosed,
Fig 1. Study flowchart. BE: bronchiectasis; CF: cystic fibrosis; COPD: chronic obstructive pulmonary
disease.
https://doi.org/10.1371/journal.pone.0177931.g001
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and the period between the onset of symptoms and the diagnosis of BE was shorter. In these
patients, distribution of BE was more frequently bilateral and a greater proportion had daily
expectoration, which was most frequently white. There was also a higher proportion of
patients with annual exacerbations (72% vs. 48%; p = 0.02).
Respiratory function data
Table 2 shows functional comparative data between the two groups. Patients with BE and
COPD had lower FVC, FEV1, FEV/FVC and SatO2 values, and most of them showed an
obstructive pulmonary pattern, even though 14% presented a non-obstructive pattern (FEV1/
FVC 0.7). A greater proportion of them had a severe or very severe functional impairment.
For the data to be comparable to those of other series published in recent years, we classified
the severity of COPD according to the latest GOLD criteria; 1.3% were at the stage GOLD I,
26.7% were at GOLD II, 38% were at GOLD III and 20% were at GOLD IV (Fig 2).
The presence of CBC was associated with poorer respiratory function, both in patients with
and without COPD. However, spirometric values were significantly lower in colonised COPD
patients, compared to non-COPD colonised patients: FVC (63.3% vs. 68.1%), FEV1 (37.1% vs.
62.7%), FEV1 / FVC (48.6% vs. 62.8%) and SatO2 (91.3% vs. 94.6%) (all comparisons p<0.001).
Microbiology data
There were no significant differences between the two groups in terms of the proportion of
patients with CBC (34.9% vs. 34.2%) or in the percentage of the various isolated
Table 1. General, clinical and radiological data.
BE without COPD
(n = 1,632)
BE with COPD
(n = 158)
p
Male sex (% of patients) 40.8 89.9 < 0.001
General data (mean ± sd)
Age (years) 63.7 ± 18.6 76.4 ± 10.4 < 0.001
Age at onset of symptoms (years) 35.6 ± 23.9 56.5 ± 16.9 < 0.001
Age at BE diagnosis (years) 48.9 ± 20.9 65.7 ± 10.9 < 0.001
Diagnosis delay (years between onset of symptoms and diagnosis of BE) 13.4 ± 16.2 9.2 ± 11.5 0.002
Clinical data (% of patients)
Current or previous smoking 32.6 96.8 < 0.001
Daily expectoration 50.8 65.2 0.001
Type of expectoration
• White
• White-yellow
• Yellow or green
• 31.4
• 32.7
• 19.0
• 40.5
• 36.7
• 15.2
0.004
Sinusitis 26.5 7.2 < 0.001
Haemoptysis 33.3 27.2 ns
Presence of exacerbations previous year 48.0 72.0 0.02
Mortality 19.0 37.5 < 0.001
BE extension (% of patients)
Localised BE 28.2 24.7 ns
Bilateral BE 48.5 57.0 0.042
Diffuse BE 23.3 18.4 ns
BE: bronchiectasis; ns: non-significant; sd: standard deviation
https://doi.org/10.1371/journal.pone.0177931.t001
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microorganisms. Seventeen different microorganisms were registered, the most common of
which were: P. aeruginosa (PA), H. influenzae and S. pneumoniae (Table 3).
The proportion of patients with CBC caused by any microorganism or, more specifically,
by PA increased with the functional severity impairment (in both cases p<0.001) in patients
both with and without COPD, with no differences observed between the groups (Fig 3A and
3B). Furthermore, both types of CBC were significantly associated with a higher percentage of
patients with exacerbations in the previous year (p<0.001 and p = 0.001, respectively). This
association was more relevant in patients with COPD and CBC by any microorganism
(p = 0.019) (Fig 4A and 4B).
Treatment
Patients with BE and COPD were treated with BD and ICS and intravenous antibiotics to a
larger extent, but there was no difference with non-COPD patients in the use of antibiotherapy
Table 2. Functional data.
BE without COPD
(n = 1,632)
BE with COPD
(n = 158)
p
FVC (%) (mean ± sd) 72.8 ± 19.3 60.2 ± 16.8 < 0.001
FEV1 (%) (mean ± sd) 69.4 ± 23.4 45.7 ± 18.0 < 0.001
FEV1/FVC (%) (mean ± sd) 71.0 ± 14.5 55.3 ± 13.9 < 0.001
SatO2 (%) (mean ± sd) 95.2 ± 3.6 92.1 ± 4.8 < 0.001
Functional severity (% of patients)
Normal or mild (FEV1 > 80%) 38.8 3.3 < 0.001
Moderate (FEV1 50–80%) 37.3 36.7 NS
Severe (FEV1 30–49%) 19.0 40.0 < 0.001
Very severe (FEV1 < 30%) 4.9 20.0 < 0.001
Type of ventilatory disorder (% of patients)
Obstructive
(FEV1/FVC < 0.7)
41.5 86.0 < 0.001
Non-obstructive
(FEV1/FVC 0.7)
58.5 14.0
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; ns: non-significant; sd: standard deviation; SatO2: oxygen saturation.
https://doi.org/10.1371/journal.pone.0177931.t002
Fig 2. Severity of patients with bronchiectasis secondary to COPD according to GOLD staging.
COPD: chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pone.0177931.g002
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(oral or inhaled) nor in the need for surgery (Table 4). When specifically analysing treatments
in terms of CBC by PA (Table 4), we observed that there were significant differences only in
ICS, which were most frequently used in COPD patients. In both groups (with/without
COPD) there was a significantly greater use of ICS, oral and inhaled antibiotics in colonised
patients.
With respect to the use of treatment in terms of respiratory functional impairment, we only
found significant differences between COPD and non-COPD patients in the use of BD (most
commonly used in COPD patients with mild impairment) (p = 0.043) and cyclic oral anti-
biotherapy (more in non-COPD patients with moderate impairment) (p = 0.046).
Survival analysis
At the time the SBHR was closed, follow-up data were available for 836 patients (46.8% of the
non-COPD group and 45.6% of the COPD group), with an average follow-up time of 3.36
years. The overall proportion of deaths was 13.8%, which was significantly higher in the
COPD group (37.5% vs. 19.0%; p<0.001) (Table 1). There were no significant differences in
the causes of death among patients with and without COPD: respiratory (87.5% vs. 66%), car-
diovascular (50% vs. 31.3%), cancer (50% vs. 56.3%) or others. When the survival between dif-
ferent groups was compared, patients with BE associated with COPD presented the highest
mortality rate, well above post-infectious (15.3%), primary immunodeficiencies (10.1%) or
unknown causes (11.1%) (Fig 5). The majority of deaths were due to respiratory causes
Table 3. Microbiological data.
BE without COPD
(n = 1,632)
BE with COPD
(n = 158)
p
Chronic bronchial infection (% of patients) 34.9 34.2 ns
Colonising microorganisms (% of patients)
Pseudomonas aeruginosa 19.8 24.7 ns
Haemophilus influenzae 12.2 8.2 ns
Streptococcus pneumoniae 5.4 3.8 ns
Aspergillus spp 3.6 2.5 ns
Candida spp 2.3 1.9 ns
Staphylococcus aureus 2.3 0.6 ns
Moraxella catarrhalis 1.3 0.6 ns
Stenotrophomonas maltophilia 0.9 1.9 ns
Escherichia coli 0.7 0 ns
Klebsiella pneumoniae 0.7 0.6 ns
Acinetobacter spp 0.6 1.3 ns
Atypical mycobacteria 0.6 1.3 ns
Alcaligenes xylosoxidans 0.4 1.9 ns
Serratia spp 0.4 1.3 ns
Bordetella spp 0.2 0.6 ns
MRSA 0.2 0.6 ns
Pseudoallescheria boydii 0.2 0 ns
Scedosporium spp 0.2 0 ns
Proteus spp 0.1 0.6 ns
Nocardia spp 0.1 0 ns
Penicillium spp 0.1 0 ns
MRSA: Methicillin-resistant Staphylococcus aureus; ns: non-significant.
https://doi.org/10.1371/journal.pone.0177931.t003
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(71.2%), although there were no significant differences between patients with or without
COPD. The multivariate analysis showed that the diagnosis of COPD in a patient with BE as a
primary diagnosis increased the risk of death by 1.77 compared to the rest of the patients, after
adjusting for age, gender, body mass index, presence of CBC caused by PA, FEV1, smoking
habit and BE extension (Table 5).
Discussion
We analysed a homogeneous and extensive sample of patients primarily diagnosed with BE,
who were subsequently diagnosed with BE related to COPD after a rigorous study. Compared
to BE associated with other conditions, patients with COPD are mostly male, older, with
poorer respiratory function, more frequent exacerbations and a higher mortality rate after
Fig 3. Presence of chronic bronchial colonisation. (A) Chronic bronchial colonisation by any microorganism
according to functional severity group. (B) Chronic bronchial colonisation by P. aeruginosa according to functional
severity group. BE: bronchiectasis: COPD: chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pone.0177931.g003
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adjusting for several confounding variables. There are no differences between them and the
remaining patients as regards the proportion of CBC, colonising microorganisms or treatment
regimen.
Given that this was a registry, assigning a specified aetiology to a particular patient depended
on the researcher’s criteria. To avoid biases, the committee who developed and coordinated the
SBHR requested that a series of recommendations be followed to diagnose and treat patients.
These recommendations were later included by SEPAR in the first published clinical guidelines
on diagnosing and treating this disease in 2008 [11], which were followed by the British guide-
lines a few years later [16]. In order to establish a diagnosis of COPD-related BE, other possible
causes should have been ruled out, but patients also had to present a clinical and functional
Fig 4. Presence of exacerbations during the previous year. (A) According to CBC by any microorganism.
(B) According to CBC by P. aeruginosa. BE: bronchiectasis; CBC: chronic bronchial colonisation; COPD:
chronic obstructive pulmonary disease; PA: Pseudomonas aeruginosa.
https://doi.org/10.1371/journal.pone.0177931.g004
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course compatible with COPD. In this respect, it was crucial that most of them were followed as
outpatients on a regular basis by the participating researchers. Furthermore, the diagnosis of BE
related to COPD was ruled out in patients with a history of smoking when another disease was
detected in the etiological study and considered to be responsible for the BE.
Table 4. Treatment data according to the presence of COPD and CBC by P. aeruginosa.
BE without
COPD
(n = 1,632)
BE with COPD
(n = 158)
p BE without COPD with CBC by
PA
(n = 323)
BE with COPD with CBC by
PA
(n = 39)
p
Inhalers (% of patients)
BD 73.5 94.0 <0.001 86.7 97.2 ns
Inhaled steroids 65.3 82.7 <0.001 80.9 94.6 0.039
Oral Antibiotherapy (% of patients)
Cyclic oral antibiotics 14.9 10.4 ns 30.0 26.3 ns
Continuous oral antibiotics 2.3 2.6 ns 7.2 5.3 ns
Inhaled Antibiotherapy (% of patients)
Inhaled cyclic antibiotics 4.0 5.5 ns 11.9 13.5 ns
Inhaled continuous
antibiotics
7.0 9.0 ns 25.4 24.3 ns
Other treatments (% of patients)
Intravenous antibiotics 77.8 89.3 0.004 75.5 84.8 ns
Surgery 4.1 2.1 ns 5.5 5.6 ns
BE: bronchiectasis; CBC: chronic bronchial colonisation; COPD: chronic obstructive pulmonary disease; ns: non-significant; PA: Pseudomonas aeruginosa.
https://doi.org/10.1371/journal.pone.0177931.t004
Fig 5. Kaplan Meier survival curve: Cumulative percentage of survivors per non-cystic fibrosis
bronchiectasis aetiology. Curves compared by means of the log-rank test: COPD curve vs. other
aetiologies curves (log-rank 38.800; p<0.0001).
https://doi.org/10.1371/journal.pone.0177931.g005
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Our series is the largest to have analysed the aetiology and clinical characteristics of patients
with BE; we observed that in 8.8% of these, COPD was considered to be the causal factor of
BE. Until recently, BE studies have included a small number of patients and also excluded
those with COPD, which limited the value of the findings [17–19]. More recent studies have
included a larger number of cases [20–23] but some do not include individual clinical data
[23]. In these series, COPD is considered to be an aetiology of BE in a higher percentage than
in ours (11–36%) [21–25]. This difference might be attributed to the fact that the SBHR’s data
were collected at a time when it was not common to consider COPD as a possible cause of BE.
We found that patients with BE and COPD had more airflow obstruction and lower FEV1,
which coincides with previous observations [5–8]. However, 14% of them presented a non-
obstructive pulmonary pattern in the spirometry performed closest to the moment of inclusion
in the registry. This can be attributed to technical reasons (incorrect spirometric manoeuvre),
but also to factors related to COPD itself or to the presence of BE. It is known that there are
patients with an obstructive pulmonary pattern who require a plethysmographic test to be
diagnosed correctly [26,27], so it is not uncommon to detect a non-obstructive spirometric
impairment in patients with airway diseases [27,28]. Moreover, a restrictive element is a fea-
ture of previous functional research into BE [28,29], and no satisfactory explanation has been
advanced for this finding. Since our study was cross-sectional, the spirometry values intro-
duced at the time of inclusion in the registry were maintained, even in the 21 COPD patients
with no obstructive pattern. However, by contacting the responsible researchers we ensured
that these patients had COPD-compatible clinical/epidemiological characteristics and spirom-
etries with an obstructive pattern during their clinical course, and that other causes of BE had
been ruled out.
The frequency of CBC and the proportion of colonising microorganisms were similar in
patients with and without COPD (34.9% vs. 34.2%), and CBC by PA was associated with
increased functional impairment and increased frequency of exacerbations. Given that we
were comparing two groups of patients with BE, no differences were expected, since the associ-
ation between CBC, low FEV1 and presence of exacerbations [30,31] is already known.
It is noteworthy that a large proportion of patients received ICS, particularly those with
CBC. Subsequent to warnings of a higher risk of pneumonia in COPD patients being treated
with ICS [32], there has been a debate on the advisability of restricting its use, especially when
CBC is present. Recent studies have revealed an increase in dose-dependent bacterial load in
patients who receive ICS [33], which could be due to a decrease in local immune defences that
Table 5. Survival analysis: Cox regression adjusted by age, gender, BE extension, body mass index,
presence of CBC caused by PA, FEV1 (% predicted), smoking habit and COPD diagnosis.
Variable B p OR IC95%
Age 0.044 0.0001 1.04 1.02–1.07
COPD presence 0.512 0.001 1.77 1.18–2.76
FEV1 (% pred) 0.113 0.001 1.12 1.09–1.97
CBC by PA 0.123 0.24 1.1 0.88–1.25
Smoking habit 0.09 0.36 1.09 0.9–1.3
Gender 0.134 0.12 1.06 0.91–1.34
BE extension 0.01 0.88 1.01 0.87–1.13
BMI 0.011 0.09 1.01 0.94–1.03
BE: bronchiectasis; CBC: chronic bronchial colonisation; COPD: chronic obstructive pulmonary disease; PA:
Pseudomonas aeruginosa.
https://doi.org/10.1371/journal.pone.0177931.t005
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would favour bacterial growth. Until there is more available evidence, use of ICS in BE should
be limited to patients with bronchial hyper-responsiveness, as recommended by the guidelines
[11,16].
CBC by PA in patients with BE of any aetiology is associated with a poorer clinical evolu-
tion [31,34,35], which leads to an attempt to reduce bacterial load with long-term antibiother-
apy. Participants in the SBHR coincided in their use of oral and inhaled antibiotics to treat
CBC in patients with BE related to COPD, even though these treatment regimens are not
included in the COPD treatment guidelines [36]. The effectiveness of long-term macrolides
has been evaluated in COPD and BE with favourable results [37,38] but the use of other oral
antibiotics to avoid exacerbations in COPD has had highly variable results: consequently, the
systematic use of such drugs is not recommended at this time [39,40]. Only two studies have
evaluated the use of inhaled antibiotics—tobramycin and levofloxacin—in a few COPD
patients, with inconclusive results [41,42]. Despite the lack of scientific evidence, it is increas-
ingly common in everyday clinical practice to treat CBC by PA in patients with BE with
inhaled antibiotics, regardless of their aetiology.
The survival analysis of the 836 patients in whom follow-up data were available showed a
significantly increased mortality in COPD patients (26.2%). The presence of COPD in patients
who had been initially diagnosed with BE increased the risk of death by 1.87 times, in line with
previous observations [9,43]. Goemmine et al [9] analysed survival in a series of 245 patients,
and also observed that patients with BE related to COPD had a higher mortality (55%), with
the risk of death increased 2.12 times. The difference with our study as regards mortality may
be due to the longer follow-up period (5.18 years), but also to the higher average age of the
patients included in their study. Despite having a sample that was three times larger, we
observed, like Goemmine et al, that patients with BE and COPD had a significantly higher
mortality than those of other BE aetiologies. This confirms the impression that these patients
form a special phenotype, different from COPD without BE, but also different from the rest of
non-CF BE.
Our study has several strengths, since we had a wide and homogeneous sample of patients
monitored by pulmonologists at specialised outpatient clinics for BE in different autonomous
communities in Spain, with data being collected systematically. Furthermore, we have studied
the characteristics of COPD patients in a BE patient cohort, in contrast to most of the studies
in this respect, which assess BE patients in a COPD patient cohort.
Our study has also some limitations, however. One of them is that the diagnosis of BE
related to COPD depended on the clinical judgement of the researcher involved, which could
favour a selection bias. Nevertheless, in order to assign a specific aetiology, researchers were
requested to reasonably rule out every other cause of BE, following a study protocol that led to
an etiological diagnosis in 72.2% of patients. Furthermore, in cases where doubts about the
diagnosis of COPD might arise, as in patients with no spirometric obstruction, the corre-
sponding researcher was contacted to minimise the possibility of a misdiagnosis. We only con-
sidered BE to be associated with COPD after confirmation of spirometric obstruction (and
exclusion of other causes of BE) in those patients whose physicians thought COPD was a key
factor due to smoking and medical history, or due to the presence of emphysema in CT (data
not recorded in the registry). Another limitation is the absence of some relevant information
due to the simplicity of the data collection process: active principles and doses of the medica-
tion used; confirmation of the quality of the spirometries; and data allowing the calculation of
the FACED [20] and BSI [44] severity scores. Finally, mortality data were available in only 836
patients, but they were similarly distributed between patients with and without COPD, so we
consider the comparative survival analysis between the two groups to be valid.
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In conclusion, patients with BE related to COPD show the same type of microbiological
characteristics and receive the same treatment regimens as patients with BE from other aetiol-
ogies, with a surprisingly high use of ICS. These patients, monitored by pulmonologists spe-
cialised in BE, follow a treatment aimed at controlling CBC by PA with long-term oral and
inhaled antibiotics, despite the fact that current COPD treatment guidelines do not envisage
this type of therapies. Their mortality is notably higher than that of the remaining patients
with non-CF BE. We believe these results would justify carrying out prospective studies aimed
at assessing the tolerance and efficiency of these treatments in COPD patients.
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